FCM
Farallon Capital Management Portfolio holdings
AUM
$21.3B
1-Year Return
23.12%
This Quarter Return
+13.51%
1 Year Return
+23.12%
3 Year Return
+87.19%
5 Year Return
+183.94%
10 Year Return
+836.54%
AUM
$14.1B
AUM Growth
+$1.66B
(+13%)
Cap. Flow
+$700M
Cap. Flow
% of AUM
4.96%
Top 10 Holdings %
Top 10 Hldgs %
32.58%
Holding
150
New
30
Increased
52
Reduced
23
Closed
23
Top Buys
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$498M |
| 2 |
Boston Scientific
BSX
|
$316M |
| 3 |
Alphabet (Google) Class C
GOOG
|
$208M |
| 4 |
Hilton Worldwide
HLT
|
$132M |
| 5 |
New York Times
NYT
|
$127M |
Top Sells
| 1 |
IAC Inc
IAC
|
$456M |
| 2 |
WUBA
58.COM INC
WUBA
|
$268M |
| 3 |
Salesforce
CRM
|
$208M |
| 4 |
Qiagen
QGEN
|
$123M |
| 5 |
CZR
Caesars Entertainment Corporation
CZR
|
$97.2M |
Sector Composition
| 1 | Healthcare | 41.8% |
| 2 | Communication Services | 18.01% |
| 3 | Technology | 8.41% |
| 4 | Financials | 7.57% |
| 5 | Industrials | 5.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BRMK
51
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
| $70.7M | 0.49% |
7,170,213
| – | – |
|
52
Apellis Pharmaceuticals
APLS
$3.55B
| $68.6M | 0.47% |
2,275,000
+25,000
| +1% | +$754K |
|
53
PG&E
PCG
$33.2B
| $68.5M | 0.47% |
+7,292,042
| New | +$68.5M |
|
54
Generation Bio
GBIO
$40.3M
| $65.5M | 0.45% |
212,063
+181
| +0.1% | +$55.9K |
|
|
SAGE
55
DELISTED
Sage Therapeutics
SAGE
| $64.2M | 0.44% |
1,050,000
+200,000
| +24% | +$12.2M |
|
56
Equifax
EFX
$30.8B
| $62.2M | 0.43% |
396,484
+141,140
| +55% | +$22.1M |
|
57
Grifois
GRFS
$6.89B
| $54.3M | 0.38% |
3,128,750
+15,528
| +0.5% | +$269K |
|
|
KRTX
58
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $54.1M | 0.37% |
700,000
+125,000
| +22% | +$9.67M |
|
59
Protagonist Therapeutics
PTGX
$3.77B
| $53.8M | 0.37% |
2,750,000
+250,000
| +10% | +$4.89M |
|
|
ARNA
60
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $47.1M | 0.33% |
629,886
-270,114
| -30% | -$20.2M |
|
61
Cytokinetics
CYTK
$6.34B
| $46.5M | 0.32% |
2,150,000
+650,000
| +43% | +$14.1M |
|
|
AMRS
62
DELISTED
Amyris Inc.
AMRS
| $40.9M | 0.28% |
14,000,000
+6,990,473
| +100% | +$20.4M |
|
63
Annexon
ANNX
$238M
| $40.4M | 0.28% |
+1,657,261
| New | +$40.4M |
|
|
ZGNX
64
DELISTED
Zogenix, Inc.
ZGNX
| $40.3M | 0.28% |
2,250,000
+250,000
| +13% | +$4.48M |
|
65
Pacific Biosciences
PACB
$381M
| $40.1M | 0.28% |
4,063,770
+1,063,770
| +35% | +$10.5M |
|
66
Zymeworks
ZYME
$1.14B
| $39.7M | 0.27% |
852,200
+302,200
| +55% | +$14.1M |
|
67
Agios Pharmaceuticals
AGIO
$2.09B
| $37.9M | 0.26% |
1,083,429
-166,571
| -13% | -$5.83M |
|
68
Lantheus
LNTH
$3.72B
| $33.6M | 0.23% |
2,650,000
+15,001
| +0.6% | +$190K |
|
|
GBT
69
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $33.1M | 0.23% |
+600,000
| New | +$33.1M |
|
70
Zentalis Pharmaceuticals
ZNTL
$126M
| $32.4M | 0.22% |
991,174
| – | – |
|
|
TVRD
71
Tvardi Therapeutics, Inc. Common Stock
TVRD
$292M
| $28.6M | 0.2% |
62,500
-1,389
| -2% | -$636K |
|
|
NVTA
72
DELISTED
Invitae Corporation
NVTA
| $25.7M | 0.18% |
593,472
-63,056
| -10% | -$2.73M |
|
|
RDUS
73
DELISTED
Radius Health, Inc.
RDUS
| $23.9M | 0.17% |
2,107,400
+7,400
| +0.4% | +$83.9K |
|
|
CLGX
74
DELISTED
Corelogic, Inc.
CLGX
| $23.3M | 0.16% |
+345,000
| New | +$23.3M |
|
75
KE Holdings
BEKE
$22.4B
| $20.5M | 0.14% |
+335,000
| New | +$20.5M |
|